Listing of Claims

The following listing of claims replaces all prior versions and listings of claims in the application.

- 1. (Original): Use of a dopamine receptor agonist or a pharmaceutically acceptable salt thereof for producing a topical pharmaceutical preparation for the local treatment of cutaneous tumours and warts.
- 2. (Currently amended): Use according to Claim 1, eharacterised in that wherein the dopamine receptor agonist is a dopamine D₂ receptor agonist.
- 3. (Currently amended): Use according to Claim 1 [[or 2]], eharacterised in that wherein the dopamine receptor agonist is bromocriptine, pergolide, selegiline, ropirinole, pramipexole or cabergolide.
- 4. (Currently amended): Use according to one of Claims 1 to 3, characterised in that in Claim 1, wherein in the case of the cutaneous tumours it is a question of cutaneous tumours of the preliminary stage of cancer or non-metastasising carcinomas of the skin.

Preliminary Amendment Attorney Docket No. 043163

- 5. (Currently amended): Use according to one of Claims 1 to 4, characterised in that in Claim 1, wherein in the case of the cutaneous tumours it is a question of actinic keratoses, basalioma or bowenoids.
- 6. (Currently amended): Use according to one of Claims 1 to 3, characterised in that in Claim 1, wherein in the case of the warts it is a question of interdigital warts, plane warts, plantar warts, vulgar warts or condyloma.
- 7. (Currently amended): Use according to one of Claims 1 to 6, characterised in that Claim 1, wherein the pharmaceutical preparation contains a dopamine receptor agonist or a pharmaceutically acceptable salt thereof in a quantity from 0.1 wt.% to 10 wt.%, relative to the pharmaceutical preparation.
- 8. (Currently amended): Use according to Claim 7, eharacterised in that wherein the pharmaceutical preparation contains a dopamine receptor agonist or a pharmaceutically acceptable salt thereof in a quantity from 0.25 wt.% to 0.5 wt.%, relative to the pharmaceutical preparation.
- 9. (Currently amended): Use according to Claim 8, characterised in that wherein the pharmaceutical preparation contains bromocriptine or a pharmaceutically acceptable salt thereof in a quantity from 0.25 wt.% to 0.5 wt.%, relative to the pharmaceutical preparation.

Preliminary Amendment Attorney Docket No. 043163

- 10. (Currently amended): Use according to one of Claims 1 to 9, characterised in that Claim 1, wherein the pharmaceutical preparation is present in the form of an ointment, a paste, a lotion, a creme or a gel.
- 11. (Currently amended): Use according to one of Claims 1 to 10, characterised in Claim 1, wherein that the pharmaceutical preparation contains conventional adjuvants, excipients and/or diluents.
- 12. (Currently amended): Use according to one of the preceding claims, characterised in that <u>Claim 1</u>, wherein the pharmaceutical preparation is applied locally onto the affected cutaneous areas once or several times a day.
- 13. (Currently amended): Use according to one of the preceding claims, characterised in that Claim 1, wherein the use of the pharmaceutical preparation is undertaken together with a medicinal treatment that is matched to the disease.
- 14. (Currently amended): Use according to one of the preceding claims, characterised in that Claim 1, wherein the use of the topical pharmaceutical preparation is undertaken together with an oral adjuvant therapy involving a dopamine receptor agonist.
- 15. (Currently amended): Use according to one of the preceding claims, characterised in that Claim 1, wherein the pharmaceutical preparation contains dimethyl sulfoxide.

Preliminary Amendment Attorney Docket No. 043163

16. (Currently amended): Use according to Claim 15, eharacterised in that wherein the pharmaceutical preparation contains 5-20 wt.% dimethyl sulfoxide, preferably 10-15 wt.%, relative to the pharmaceutical preparation.